Paying an ode to different genres like Instrumental, Punjabi & Bengali along with independent artists
Mumbai 3rd June, 2010: For all fans of ArtistAloud.com, the month of June is going to be a TREAT with music that promises to fulfill every listener’s palette. Different genres will be highlighted every week starting with Instrumental followed by Punjabi, Bengali and finally showcasing the individual style of well known reality show contestants and winners. The music showcasing starts on 1st June and continues till 30th June exclusively on Artistaloud.com
1st week : Instrumental
We celebrate Instrumental Music through Srimallya, Babu Choudhary, Pralay and Dhwani
2nd Week Punjabi
Almost becoming the 2nd National Language of India, we celebrate Punjabi on ArtistAloud.com through the various styles and genres and artists we have on board namely Rincy T, Baba Honeey, Dilpreet Bhatia, Nakash Sargam, Jaswinder Singh, Reo
3rd Week: Bengali
One of the most growing language preferences on the platform. Presenting this week is the Bengali artists on ArtistAloud.com. Check out Deenga, Debashish Banerji, Rimita Mukherjee, Ritika Sahni
4th Week: Independent artist
We feel most proud of this week as we believe we are making a difference in the industry here. With the onslaught of reality shows in the TV industry, a lot of talented singers and musicians have had the opportunity to make it to the limelight but they go out building a career singing other people’s songs. We are proud to believe that we have made talented reality show talents to realise that they need to create a name for themselves with there own music. Hence this week is dedicated to artists who have come out of Reality Shows and we present their music through Himani Kapoor, Aishwarya Majmudar, Uvie, Arindam Chakraborty, Abhinanda Sarkar, Abbhas & Shreyas, Avanti Patel
So log on to www.artistaloud.com to experiment with different genres and satisfy your music palette.
About Artistaloud.com To experience the sound, the audience on Artistaloud.com can sample the music for free with a one minute preview of each song. If one wishes to listen to the complete song, it can be downloaded using two price packs – single download at INR 10 and a value pack that allows you to download four songs at INR 20. The songs are made available in mp3 format, for both PC and Mobile devices.
The Artistaloud.com library can also be accessed through Hungamaâs domestic and international digital distribution partnerships comprising, mobile operators, Hungama.com the BSNL storefront, iTunes, Rhapsody, Amazon MP3 to name a few, and through the Tata Sky DTH platform.
Datamonitor attended this year’s International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.
Pfizer: remains a small presence in the osteoporosis market
The presence of Pfizer at the congress suggests that the company intends to launch Conbriza (bazedoxifene) in the European market after it was approved in 2009. It is Datamonitor’s understanding that the company is negotiating price and reimbursement issues prior to launching the drug, possibly by the end of the year. On the other hand, Pfizer’s other drug Fablyn (lasofoxifene) was not mentioned at the congress, reinforcing Datamonitor’s opinion that Pfizer itself will never launch the drug.
Conbriza – also known as Viviant in the US – is a novel once-daily oral selective estrogen receptor modulator (SERM) developed by Pfizer for the treatment of postmenopausal osteoporosis. Conbriza was approved by the European Medicines Agency (EMA) in April 2009, but has not yet launched and is currently being reviewed by the FDA for the same indication. Conbriza was also filed in Japan in 2007.
There have been several safety and efficacy issued with the use of SERMs for osteoporosis which have resulted in the recent decrease in sales of the only drug in this class on the market, Eli Lilly’s Evista (raloxifene). Pfizer made an effort to improve the clinical attractiveness of its drug at the congress by presenting several posters analyzing gynecological, cardiovascular and breast safety after five years of treatment. However, it remains unclear if this will be sufficient to convince the FDA regarding Conbriza’s safety. Pfizer also presented a two-year extension to the three-year pivotal trial for bazedoxifene. Importantly, the study showed efficacy of bazedoxifene in preventing non-vertebral fractures in women with severe osteoporosis. However, In Datamonitor’s opinion these data were not very solid and Conbriza’s efficacy in preventing non-vertebral fracture among all women in the trial was statistically insignificant. As new therapies reach the market, Datamonitor believes that physicians remain skeptical of the use of these drugs for the treatment of osteoporosis.
Sanofi-Aventis/Warner Chilcott: alliance for better bone health presents GLOW results
Sanofi-Aventis has been marketing the leading brand Actonel (risedronate) in the US since its launch a decade ago. At the congress, alongside its new partner Warner Chilcott, the French pharmaceutical giant provided data from the GLOW study (Global Longitudinal Study of Osteoporosis in Women). GLOW is a prospective study involving over 60,000 women in the US, Canada, Europe and Australia. Group analysis showed that in Northern Europe only 13% of women involved were using anti-osteoporosis medications, while in the US and Canada up to 32% of women were treated. The percentage of diagnosed and treated women was also the lowest in Europe (45-52%) compared to the other regions (62-65%). The study also showed that women in the US were three times more likely to be treated than women in Southern Europe.
Out of the 5,321 women in GLOW who were taking osteoporosis drugs at baseline, 19% had stopped after the first year. The most common reason was due to doctor’s advice (37%) or side effects or long-term risk concerns (37%). No particular differences were seen in the discontinuation patterns and reasons among women who were taking bisphosphonates or non-bisphosphonate drugs. Datamonitor believes that this is a very interesting study which will allow researchers to better understand the behavior of women in taking the osteoporosis medications.
GlaxoSmithKline: displays continued interest in the osteoporosis market
GlaxoSmithKline’s presence at the conference demonstrated its continued commitment to osteoporosis. Together with its partners Amgen and Roche, it hosted key lunch symposia on denosumab and Bonviva. The company also presented data regarding its calcilytic compound ronacaleret, which recently failed Phase II trails.
Investigation of ronacaleret was terminated after Phase II trials failed to show efficacy of the compound in increasing bone mineral density (BMD). The calcium-sensing receptor in parathyroid cells regulates the secretion of parathyroid hormone (PTH). By antagonizing the receptor it was thought that there would be an increase in PTH secretion and therefore an increase in BMD.
The Phase II data presented were from a dose finding study (100mg, 200mg, 300mg or 400mg) and included an active comparator (alendronate 70mg) and an open label teriparatide arm. It was seen that patients taking ronacaleret had experienced an increase in lumbar spine BMD but this was lower than what was seen in patients taking alendronate and teriparatide. The authors suggest that ronacaleret caused a mild sustained primary hyperparathyroidism and did not produce the anabolic effect that had been anticipated from preclinical trials.
Datamonitor notes that there are several other similar compounds in development for the treatment of osteoporosis. The negative data presented at the conference could suggest that there is a class issue with these novel compounds and therefore they may never reach the market. Nevertheless, experts at the congress are still very intrigued by the compounds and believe that others may be more efficacious in increasing BMD. As such, Datamonitor believes that calcilytic compounds remain attractive therapeutic targets for the time being.
Datamonitor: Pipeline and Commercial Insight: Osteoporosis – Novel agents to battle for payer acceptance:
www.reports-research.com/studien/pipeline-commercial-insi…
markt-studie.de, founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal reports-research.com was introduced due to the extraordinary success of the portal. Again one year later estudio-mercado.es – the Spanish spoken portal – was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market surveys from more than 200 international publishers, current market data for more than 6,000 branches worldwide, 10,000 company profiles as well as a free-of-charge research and recommendation service for individual market research.
This year on May 26, the world unites once more in the MS movement to highlight the international effects of multiple sclerosis (MS). Organized by the Multiple Sclerosis International Federation (MSIF) with the help of MS Societies in 62 countries, including the United States and Canada, the day will be marked by more than 200 events around the world in a concerted effort to build awareness for MS and enhance collaboration that will bring us closer to a world free of multiple sclerosis.
The focus of World MS Day is on the needs of people with multiple sclerosis, the economic impact of MS, and the urgent need for more research to eradicate the disease. It encourages people affected by MS worldwide to think globally and act locally coming together to take positive action in the MS movement by sharing experiences, by donating time and funds to both support MS programs that will help people with MS move forward with their lives and by spurring MS research to end the disease.
This year to bring home the importance of what an MS diagnosis can mean, which occurs hourly in the US, the MSIF initiated the first global survey covering 125 countries and examining the “Global Impact of Multiple Sclerosis.” Estimates among the 15 nations tracking such data, indicate that the average annual costs of MS to the person affected and society as a whole to be $41,335, and most currently in the US, $69,118. Based on an MS population in the U.S. of 400,000 that would mean the total yearly impact of MS in the United States is $28 billion. Loss of employment, or early retirement, was considered to be the single largest factor contributing to this financial cost.
MS is found in every country in the world, and is one of the most common neurological diseases amongst people in their 20s and 30s. It is a prime of life disease striking just when people are building their careers and families. MS affects at least twice as many women as men and up to 60% of people diagnosed with MS will experience long-term disability. Though continuing medical breakthroughs have brought partially effective treatment to many people with MS, there is still no cure.
How to Get Involved in World MS Day
Think globally and act locally by:
Registering at www.worldmsday.org
Volunteering at your local Society chapter
Text MSAWARE to 20222 to donate $5 to the National MS Society
“World MS Day is so important because it reinforces that MS is a global disease, which demands global awareness, a global movement and global action,” said Joyce Nelson, President and CEO of the U.S. National MS Society.
HIGHLIGHTS MARKING WORLD MS DAY
Names You Know
Walter Williams, living legend and co-founder of the hit R&B group The O’Jays has chosen World MS Day to announce that he is a part of the global MS Movement and has been successfully living and working with MS, thanks in large part to the help of disease modifying therapies, for more than 25 years. Just some of The O’Jays hit songs include “Love Train,” “Lovin’ You,” and “For the Love Of Money.” Walter was inducted in the Rock and Roll Hall of Fame in 2005. www.nationalMSsociety.org
To tie into this heartfelt message by Walter Williams to give hope and encouragement to those living with MS, and with the assistance of Clear Channel Communications, the Society developed a set of radio public service announcement to reach out to African Americans and to Hispanics who are often under diagnosed and under served.
Alessandra Ambrosio ? Victoria’s Secret Super model has recorded a special message in support of World MS Day in honor of her dad who has multiple sclerosis. www.youtube.com/nationalmssociety
Clay Walker ? country music star is doing a live Twitter Q&A 7PM, EST. Tweet your questions to @ClayWalker using #WorldMSDay hash tag (http://twitter.com/ClayWalker)
Milind Soman – Bollywood actor/model will be running along the Great Wall of China
Research Advances
MS Stem Cell Research
Researchers, working with a panel of people impacted by MS, pave the way for the first coordinated international approach to MS stem cell research by publishing a consensus guide on the future of stem cell transplantation research which establishes a coordinated global approach to speed research, the development of potential therapies, and improve patient access to stem cell clinical trials. http://www.mssociety.org.uk/document.rm?id=7495
Small-scale trials of stem cells, such as adult mesenchymal stem cells (from bone marrow and other bodily tissues), are underway: http://www.nature.com/clpt/journal/vaop/ncurrent/abs/clpt201044a.html
CCSVI Research
Coordinating and leveraging the resources available through the worldwide network of MS Societies, an international review panel is meeting to determine initial CCSVI grants to be announced on June 14th: http://www.nationalmssociety.org/research/intriguing-leads-on-the-horizon/ccsvi/index.aspx
Fast Forward
The Society’s subsidiary devoted to bridging the gap between research and drug development has announced funding for new biotech companies — Canbex Therapeutics, Ltd.in London for the development of treatment for spasticity and Five Prime Therapeutics, Inc. in San Francisco for pre-clinical testing of biological molecule. www.fastforward.org
Campaigns To Follow
WPTÂź Texas Hold ‘Em Poker on Facebook, the most popular international poker brand is now available on the Facebook platform as a free-to-play game developed by FunClick. They are offering a two-week Chips for Charity promotion to support MS research. For details visit http://www.funclickgames.com/chipsforcharity. To become a fan of WPT Texas Hold ‘Em Poker please visit http://www.facebook.com/playwpt or follow @PlayWPT on Twitter.
We Keep Moving culminates its 10-week reality road trip across America where it chronicled the stories of people living with MS who are moving their lives forward despite challenges. The unique interactive documentary is told by a creative team living with MS themselves. Each week, visitors to the site voted to determine the film crew’s weekly destination. In 10 weeks the crew crisscrossed the country and traveled well over 100,000 miles to tell the stories of people living with MS: www.wekeepmoving.org
From Zurich To Venice, a group of 15 international cyclists led by the renowned art dealer Nick Maclean are bicycling from Zurich to Venice in support of World MS Day to raise funds for MS research, in particular the neuro-repair project sponsored by the Society at Johns Hopkins. They’ve already raised several hundred thousand dollars.
In Other Parts of the World http://worldmsday.blogspot.com:
The rock group U2 has lent support to the goals of World MS Day by donating the use of their song “Beautiful Day” as the anthem for the global MS campaign film.
In Australia ? there will be groups of people wearing red lipstick encouraging people to “Kiss goodbye to MS.”
In Canada ? Supporters are being asked to host MS Global Dinner parties to help fund MS research; a special teleconference is being held to give participants an opportunity to learn more about MS research; and an on-line advocacy campaign is underway to improve income security for people living with MS
In Chile ? There will be volunteers handing out green apples, the symbol of their Society.
In Denmark ? There will be a cross country tour featuring “Researcher in a Box”.
In Germany ? There will be a special concert, a showing of the World MS Day film at nearly 1,500 locations across the country, and a cycling event.
In Turkey ? There will be an exhibition of painting by people living with MS, a cycling event, a special concert, and a day long conference on MS.
The following resources are available:
On the World MS Day site
http://media.msif2.org/pressroom/ Username ? media / password ? Jupiter4
World MS Day film with the music of U2 (1 minute or 3.5 minute versions)
National Multiple Sclerosis Society World MS Day page: http://www.nationalMSsociety.org/worldMSday
Possible interviews with Walter Williams, Alessandra Ambrosio and Clay Walker
Interviews with MS researchers and individuals living with MS in your area
World MS Day initiatives are taking place in the following countries:
Argentina, Australia, Austria, Belgium, Bosnia & Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Egypt, Estonia, Finland, France, Germany, Ghana, Greece, Hungary, Iceland, India, Ireland, Italy, Japan, Jordan, Luxembourg, Malaysia, Montenegro, Morocco, Netherlands, Nicaragua, Norway, Pakistan, Palestinian Authority, Paraguay, Peru, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Tunisia, Turkey, United Arab Emirates, UK, Uruguay, USA.
About the U.S. National Multiple Sclerosis Society
MS stops people from moving. The National MS Society exists to make sure it doesn’t. The Society addresses the challenges of each person affected by MS by funding cutting edge research, driving change through advocacy, facilitating professional education, collaborating with MS organizations around the world, and providing programs and services designed to help people with MS and their families move their lives forward. In 2009 alone, through our national office and 50 state network of chapters, we devoted over $132 million to programs that enhanced more than one million lives. To move us closer to a world free of MS, the Society also invested nearly $40 million to support 375 research projects around the world. To learn more about multiple sclerosis and the service programs the Society offers visit www.nationalMSsociety.org.
About Multiple Sclerosis
Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Every hour in the United States, someone is newly diagnosed with MS. Symptoms range from reduced or lost mobility to numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 400,000 people in the U.S., and 2.1 million worldwide.
Forest Laboratories, Inc. and Almirall, S.A. announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters. In addition, 3 posters reporting data on the GenuairÂź inhaler, which is used to administer the compounds, will be presented.
âWe are pleased to have the opportunity, along with our partner Almirall, to present data on two of our key pipeline products at the ATS conference. The data presented here reinforce the commitment we have to the development of useful treatments for important respiratory diseases,â said Lawrence S. Olanoff, President and Chief Operating Officer of Forest Laboratories.
Key Aclidinium Bromide Data â Tuesday, May 18th
The following study results will be presented:
Efficacy and safety of aclidinium bromide 400 ”g BID compared with placebo and tiotropium in patients with moderate to severe COPD (F77, H. Magnussen)
Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD (F65, F. Maltais)
Safety and tolerability of aclidinium bromide administered intravenously and absolute bioavailability of inhaled aclidinium bromide in healthy subjects (F101, S. Ortiz)
Pharmacokinetics of aclidinium bromide 200 ”g and 400 ”g in young and elderly patients with chronic obstructive pulmonary disease (F83, S. de la Motte)
Metabolism and excretion of aclidinium bromide following intravenous administration of [14C] aclidinium bromide in healthy subjects (F100, S. Flach)
In addition, two preclinical studies characterizing the profile of aclidinium by comparison to glycopyrrolate will be presented (A55, J. Beleta and F85, A. Galvada).
Key LAS100977 Data â Wednesday, May 19th
The following two clinical posters will be presented:
Efficacy and safety of single inhaled doses of LAS100997, a novel long acting B2-agonist in patients with persistent asthma (221, J. Beier)
Single doses of LAS100977, a novel long acting beta 2-agonist, show high activity and long duration in healthy subjects (E31, W. Timmer)
In addition, two preclinical studies assessing the potency, selectivity and duration of action for LAS100977 will be presented (E43, M. Aparici and E44, M. Miralpeix).
GenuairÂź Inhaler Data
Three posters assessing the reliability of the technical features of the inhaler, stability of aclidinium bromide in the inhaler under various storage conditions, and aerodynamics and particle size of aclidinium bromide administered using the inhaler will be presented (B57, R. Greguletz, B56, K. Block, and B58, K. Block).
“The studies being presented here demonstrate that aclidinium bromide administered BID provides significant bronchodilation and is well tolerated,â said Per-Olof Andersson, Chief Scientific Officer at Almirall. “Additionally the results of the LAS100977 studies show that the compound has potential for the treatment of respiratory diseases. The presentations further explain the reliability and technical features of the GenuairÂź inhaler used to effectively deliver both compounds.”
About aclidinium bromide and the GenuairÂź inhaler
Aclidinium bromide, which is in Phase III testing for COPD, is a novel, long-acting inhaled anticholinergic bronchodilator which has a long residence time at the M3 receptors and a shorter residence time at the M2 receptors. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Forest Laboratories, Inc. licensed U.S. rights for aclidinium from Almirall, while Almirall maintains rights for the rest of the world. The companies are jointly involved in the development of the compound.
Aclidinium bromide is administered to patients using a novel, state-of-the-art multidose dry powder inhaler (MDPI), GenuairÂź. The GenuairÂź inhaler was designed with an easy-to-use intuitive feedback system, which through a ‘colored control window’ and an audible click confirms that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates significant safety features such as an anti-double-dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
GenuairÂź is a trademark owned by Almirall, S.A.
About LAS100977
LAS100977 is a highly potent, novel, once daily long-acting beta 2-agonist (LABA) that in early Phase II testing demonstrated fast onset and long-lasting (24-hour) bronchodilating effects with a good tolerability profile in patients with stable asthma after multiple dosing. Forest entered an agreement with Almirall to develop, market and distribute LAS100977 in the United States in December 2009. The compound will be developed in combination with an undisclosed corticosteroid using Almirall’s proprietary GenuairÂź inhaler for the treatment of both asthma and COPD.
About Almirall
Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercializes its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.
Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 11 affiliates.
For further information, please visit www.almirall.com.
About Forest Laboratories
Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people’s lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest’s current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com
Building on 175 years of expertise in the care for mothers and infants, Brigham and Women’s Hospita l (BWH) announces the launch of The Stork Fund, a new ePhilanthropy venture dedicated to supporting healthy moms, pregnancies and babies. The Stork Fund will raise funds for clinical care, research and education and be directed to programs connected to gynecology, fertility, pre- and post- natal care, delivery, birth equity and neonatal intensive care.
“As a leader in women’s health and the premiere birthing center for expectant mothers in the Boston area, we are dedicated to providing quality, family-focused care. Our patients are always looking for ways to stay connected and The Stork Fund is the perfect opportunity for them to give thanks and show appreciation to their care-givers,” said Jim Asp, VP and Chief Development Officer.
With more than 8,000 births annually, BWH is one of the most trusted names in women’s health and is the birthing center most women in Massachusetts choose. The Center for Women and Newborns at the Mary Horrigan Connors Center for Women’s Health at BWH is world renowned for quality obstetrical and neonatal care and provides individual attention for moms, babies and families. BWH is dedicated to the most comprehensive range of state-of-the-art obstetrical services.
“We are excited about the launch of The Stork Fund which will allow us to continue to focus on delivering high-quality care to moms and babies and to improve this care through research and education. The innovations and programs that we develop and the work we do at BWH impacts hospitals and new moms across the United States and beyond,” said Marikim Bunnell, MD, a physician in the Obstetrics/Gynecology Department at BWH.
The Stork Fund will officially kick off with a “My Baby and Me” event on Saturday May 1 at the Prudential Center in Boston, MA. The event is open to all moms, dads and children under 5 years-old and features Isis Parenting yoga classes for moms and kids and lunch and snacks provided by Au Bon Pain.
The Stork Fund is BWH’s first official venture into ePhilanthropy and will also include an e-store where 100% of the proceeds from Stork Fund products such as bibs, blankets and onesies will benefit the fund.
Visit StorkFund.org for information on how you can make a donation to support the nurses, doctors, research and clinical staff at BWH.
Brigham and Women’s Hospital (BWH) is a 777-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. In July of 2008, the hospital opened the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 860 physician-investigators and renowned biomedical scientists and faculty supported by more than $416 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses’ and Physicians’ Health Studies and the Women’s Health Initiative.
Nationally-known expert Kenneth Doka, Senior Bereavement Consultant to Hospice Foundation of America (HFA), will host a discussion focusing on the role that the Internet plays in the lives of grieving young people and the implications for clinicians during Hospice Foundation of America’s (HFA’s) live online webinar on Tuesday, June 15 from 1pm?2:30pm EDT. Dr. Doka will be joined by Dr. Carla Sofka, Associate Professor of Social Work at Siena College in New York, and Pamela Gabbay, Program Director of The Mourning Star Center for Grieving Children in Palm Desert, California.
“For young people, the Internet is an essential source of communication and information,” says Dr. Doka. “So it is natural they would turn to the Internet when they grieve.” Participants will learn both the advantages and disadvantages of utilizing the Internet in grief and learn strategies for opening a dialog with children and adolescents about the ways the use the Internet as they mourn. The clinical implications of research of Internet use for intervention with children and adolescents and their families will be examined, describing the possibilities and limitations for adults or organizations to offer support in a monitored, safe way.
“It is essential that counselors, clergy, social workers, child life specialists, educators, guidance counselors, funeral director, and parents understand what Dr. Sofka has defined as “thanatechnology”?the use of technology in death and grief-related issues,” says Amy Tucci, President and CEO of HFA. “This webinar offers an excellent opportunity to learn more about both the research and the practical use of these resources with grieving young people.”
The Organization Registration Fee is $100, which allows access to both the live webcast and an archived online program for one year past the live webinar, with unlimited CEs (1.5 hours) available for a wide range of professions. Individuals may register for the live webinar for $35 and 1.5 hours of CE credit is included for the registered individual. This webinar is part of a three-part series sponsored by the Moyer Foundation; a Registration Fee of $250 allows unlimited access and CEs for one year to all three webinars in the series.
To learn more about this exciting educational offering, contact HFA at 800-854-3402 or go to http://www.hospicefoundation.org/education/webinars
Kaeng Raeng LLC, a nutraceutical company based in Silicon Valley, exhibited at Natural Products ExpoWest in Anaheim, CA, March 12-14 2010. As a new detox/cleanse company in the âHot Productsâ Hall, Kaeng Raeng attracted several buyers and members of the press, including VitalJuice.com who named Kaeng Raeng âThe Next Cleanseâ and a âTrend You Have to Tryâ in their March 17 newsletter. VitalJuice.com reaches affluent women in major cities including New York, Los Angeles, Chicago, and San Francisco.
âThis weekend, your intrepid editors ate their way through Natural Products Expo West,â the article said. âSome stuff was ehh, other items were good, but we saved the very best for our readers. The Next Cleanse: Kaeng Raeng. Tired of spicy lemonade? This vegan, gluten-free and caffeine-free cleanse packs fruit and probiotics to jump-start weight loss. Mix a packet of powder with water, milk or yogurt at mealtime; you can eat as many raw fruits and veggies as you like.â
Animal Rights Campaign
Kaeng Raeng is proud to continue its support of animal rights organizations and animal free products. A portion of every sale in 2010 will go to support The Humane Society, Americaâs largest animal protection organization. âPersonally as a vegan I am committed to animal rights and supporting an animal free lifestyle,â Lindsay Reinsmith, founder and CEO, said. âThis is an exciting opportunity for Kaeng Raeng, as an animal free product, to support one of Americaâs finest organizations.â
Product Updates
KR detox will soon be available to stores in individual trial packet form.
âWeâre happy to offer consumers the opportunity to taste the product before committing to a full program,â Reinsmith said. âFor best results, consumers should complete the full program, so weâre still encouraging stores to carry our best-selling 3-Day Beginner to ensure customer satisfaction.â Trial packets retail for $6.50 each and will be available with POP retail displays in April.
Due to consumer demand, KRâs probiotic blend will switch to L. Acidophilus. âMainstream consumers are familiar with L. Acidophilus and wanted it in Kaeng Raeng,â Reinsmith said. âWeâre committed to our customers and keeping our product 100% all natural, simple, and convenient. We use no artificial colors, flavors, or sweeteners and no preservatives. If consumers canât pronounce an ingredient, we donât include it!â
Kaeng Raeng is co-packaged by Multivitamin Direct and headquartered in Palo Alto, CA. Samples and CEO interviews available upon request. Contact press@kaengraeng.com or call 650 963 4943.
